High-conductance calcium-activated potassium channels

• BAILEY MA, CANTONE A, YAN Q et al.: Maxi-K channels contribute to urinary potassium excretion in the ROMK-deficient mouse model of Type II Bartter's syndrome and in adaptation to a high-K diet. Kidney Int. (2006) 70(1):51-59.
   PubMed Web of Science ®Google Scholar
• BRENNER R, CHEN QH, VILAYTHONG A et al.: BK channel β4 subunit reduces dentate gyrus excitability and protects against temporal lobe seizures. Nat. Neurosci. (2005) 8(12):1752-1759.
   PubMed Web of Science ®Google Scholar
• LEDOUX J, WERNER ME, BRAYDEN JE et al.: Calcium-activated potassium channels and the regulation of vascular tone. Physiology (Bethesda) (2006) 21:69-78.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-FERNANDEZ JM, TOMAS M, VAZQUEZ E et al.: Gain-of-function mutation in the KCNMB1 potassium channel subunit is associated with low prevalence of diastolic hypertension. J. Clin. Invest. (2004) 113(7):1032-1039.
   PubMed Web of Science ®Google Scholar
• PICKKERS P, DORRESTEIJN MJ, BOUW MP et al.: In vivo evidence for nitric oxide-mediated calcium-activated potassium-channel activation during human endotoxemia. Circulation (2006) 114(5):414-421.
   PubMed Web of Science ®Google Scholar
• WERNER ME, ZVARA P, MEREDITH AL et al.: Erectile dysfunction in mice lacking the large-conductance calcium-activated potassium (BK) channel. J. Physiol. (2005) 567(Part 2):545-556.
   PubMed Web of Science ®Google Scholar
• CHRIST GJ, DAY N, SANTIZO C et al.: Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am. J. Physiol. Heart Circ. Physiol. (2004) 287(4):H1544-H1553.
   PubMed Web of Science ®Google Scholar
• MELMAN A, ZHAO W, DAVIES KP et al.: The successful long-term treatment of age related erectile dysfunction with hSlo cDNA in rats in vivo. J. Urol. (2003) 170(1):285-290.
   PubMed Web of Science ®Google Scholar
• MELMAN A, BAR-CHAMA N, MCCULLOUGH A et al.: hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum. Gene Ther. (2006) 18:(1165-1176.
   Google Scholar
• MELMAN A, BAR-CHAMA N, MCCULLOUGH A et al.: The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur. Urol. (2005) 48(2):314-318.
   PubMed Web of Science ®Google Scholar
• THORNELOE KS, MEREDITH AL, KNORN AM et al.: Urodynamic properties and neurotransmitter dependence of urinary bladder contractility in the BK channel deletion model of overactive bladder. Am. J. Physiol. Renal Physiol. (2005) 289(3):F604-F610.
   PubMed Web of Science ®Google Scholar
• HERRERA GM, ETHERTON B, NAUSCH B et al.: Negative feedback regulation of nerve-mediated contractions by KCa channels in mouse urinary bladder smooth muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 289(2):R402-R409.
   Google Scholar
• GRIBKOFF VK, STARRETT JE JR, DWORETZKY SI et al.: Targeting acute ischemic stroke with a calcium-sensitive opener of Maxi-K potassium channels. Nat. Med. (2001) 7(4):471-477.
   PubMed Web of Science ®Google Scholar
• SCHRODER RL, JESPERSEN T, CHRISTOPHERSEN P et al.: KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology (2001) 40(7):888-898.
   PubMed Web of Science ®Google Scholar
• AMBERG GC, SANTANA LF: Downregulation of the BK channel β1 subunit in genetic hypertension. Circ. Res. (2003) 93(10):965-971.
   PubMed Web of Science ®Google Scholar
• VALVERDE MA, ROJAS P, AMIGO J et al.: Acute activation of Maxi-K channels (hSlo) by estradiol binding to the β subunit. Science (1999) 285(5435):1929-1931.
   PubMedGoogle Scholar
• EGHBALI M, TORO L, STEFANI E: Diminished surface clustering and increased perinuclear accumulation of large conductance Ca2+-activated K+ channel in mouse myometrium with pregnancy. J. Biol. Chem. (2003) 278(46):45311-45317.
   PubMedGoogle Scholar
• BRENNER R, PEREZ GJ, BONEV AD et al.: Vasoregulation by the β1 subunit of the calcium-activated potassium channel. Nature (2000) 407(6806):870-876.
   PubMed Web of Science ®Google Scholar
• ORIO P, ROJAS P, FERREIRA G et al.: New disguises for an old channel: MaxiK channel β-subunits. News Physiol. Sci. (2002) 17:156-161.
   PubMedGoogle Scholar
• AMBERG GC, BONEV AD, ROSSOW CF et al.: Modulation of the molecular composition of large conductance, Ca2+ activated K+ channels in vascular smooth muscle during hypertension. J. Clin. Invest. (2003) 112(5):717-724.
   PubMed Web of Science ®Google Scholar
• NIEVES-CINTRON M, AMBERG GC, NICHOLS CB et al.: Activation of NFATc3 down-regulates the beta1 subunit of large conductance, calcium-activated K+ channels in arterial smooth muscle and contributes to hypertension. J. Biol. Chem. (2007) 282(5):3231-3240.
   PubMedGoogle Scholar
• MCGAHON MK, DASH DP, ARORA A et al.: Diabetes downregulates large-conductance Ca2+-activated potassium {β}1 channel subunit in retinal arteriolar smooth muscle. Circ. Res. (2007).
   PubMedGoogle Scholar
• DU W, BAUTISTA JF, YANG H et al.: Calcium-sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder. Nat. Genet. (2005) 37(7):733-738.
   PubMed Web of Science ®Google Scholar
• HERRINGTON J, MCMANUS O, KISS L: The road ahead and how to get there. Eur. Pharm. Rev. (2005) 10(3):79-84.
   Google Scholar
• GARCIA ML, KACZOROWSKI G: Critical success. Eur. Pharm. Rev. (2006) 11(2):42-45.
   Google Scholar
• MORA TC, SUAREZ-KURTZ G: Effects of NS1608, a BK(Ca) channel agonist, on the contractility of guinea-pig urinary bladder in vitro. Br. J. Pharmacol. (2005) 144(5):636-641.
   PubMedGoogle Scholar
• SUAREZ-KURTZ G, GARCIA ML, KACZOROWSKI GJ: Effects of charybdotoxin and iberiotoxin on the spontaneous motility and tonus of different guinea pig smooth muscle tissues. J. Pharmacol. Exp. Ther. (1991) 259(1):439-443.
   PubMedGoogle Scholar
• MARIJIC J, LI Q, SONG M et al.: Decreased expression of voltage- and Ca(2+)-activated K(+) channels in coronary smooth muscle during aging. Circ. Res. (2001) 88(2):210-216.
   PubMed Web of Science ®Google Scholar
• TANG XD, GARCIA ML, HEINEMANN SH et al.: Reactive oxygen species impair Slo1 BK channel function by altering cysteine-mediated calcium sensing. Nat. Struct. Mol. Biol. (2004) 11(2):171-178.
   PubMed Web of Science ®Google Scholar
• ARGENTIERI TM, BUTERA JA: An overview of potassium channel activators for the treatment of overactive bladder: a survey of new structures 2000 – 2005. Expert Opin. Ther. Patents (2006) 16(5):573-585.
   Web of Science ®Google Scholar
• NARDI A, CALDERONE V, CHERICONI S et al.: Natural modulators of large-conductance calcium-activated potassium channels. Planta Med. (2003) 69(10):885-892.
   PubMedGoogle Scholar
• WU SN: Large-conductance Ca2+- activated K+ channels: physiological role and pharmacology. Curr. Med. Chem. (2003) 10(8):649-661.
   PubMedGoogle Scholar
• CALDERONE V: Large-conductance, Ca(2+)-activated K(+) channels: function, pharmacology and drugs. Curr. Med. Chem. (2002) 9(14):1385-1395.
   PubMed Web of Science ®Google Scholar
• NARDI A, CALDERONE V, OLESEN SP: Potassium channel openers: the case of BK channel activators. Lett. Drug Design Discov. (2006) 3(4):210-218.
   Google Scholar
• HEWAWASAM P, MEANWELL NA, GRIBKOFF VK et al.: Discovery of a novel class of BK openers: enantiospecific synthesis and BK channel opening activity of 3-(5-chloro-2-hydroxyphenyl)-1, 3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one. Bioorg. Med. Chem. Lett. (1997) 7(10):1255-1260.
   Google Scholar
• VRUDHULA VM, DASGUPTA B, QIAN-CUTRONE J et al.: Atropisomeric 3-(β-hydroxyethyl)-4-arylquinolin-2-ones as Maxi-K potassium channel openers. J. Med. Chem. (2007) 50(5):1050-1057.
   PubMedGoogle Scholar
• HEWAWASAM P, FAN W, COOK DA et al.: 4-Aryl-3-(mercapto)quinolin-2-ones: novel Maxi-K channel opening relaxants of corporal smooth muscle. Bioorg. Med. Chem. Lett. (2004) 14(17):4479-4482.
   PubMed Web of Science ®Google Scholar
• ROMINE JL, MARTIN SW, MEANWELL NA et al.: 3-[(5-Chloro-2-hydroxyphenyl)methyl]5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, BMS-191011: opener of large-conductance Ca(2+)-activated potassium (Maxi-K) channels, identification, solubility, and SAR. J. Med. Chem. (2007) 50(3):528-542.
   PubMedGoogle Scholar
• HANSEN RS, DINESS TG, CHRIST T et al.: Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Mol. Pharmacol. (2006) 69(1):266-277.
   PubMedGoogle Scholar
• BIAGI G, GIORGI I, LIVI O et al.: Synthesis and biological activity of novel substituted benzanilides as potassium channel activators V. Eur. J. Med. Chem. (2004) 39(6):491-498.
   PubMedGoogle Scholar
• BUTERA JA, ANTANE SA, HIRTH B et al.: Synthesis and potassium channel opening activity of substituted 10H-benzo[4,5]furo[3,2-b]indole-and 5,10-dihydro-indeno[1,2-b]indole-1-carboxylic acids. Bioorg. Med. Chem. Lett. (2001) 11(16):2093-2097.
   PubMed Web of Science ®Google Scholar
• ANGELICO P, GUARNERI L, VELASCO C et al.: Effect of cyclooxygenase inhibitors on the micturition reflex in rats: correlation with inhibition of cyclooxygenase isozymes. BJU Int. (2006) 97(4):837-846.
   PubMed Web of Science ®Google Scholar
• TANAKA M, SASAKI Y, KIMURA Y et al.: A novel pyrrole derivative, NS-8, suppresses the rat micturition reflex by inhibiting afferent pelvic nerve activity. BJU Int (2003) 92(9):1031-1036.
   PubMed Web of Science ®Google Scholar
• MALYSZ J, BUCKNER SA, DAZA AV et al.: Functional characterization of large conductance calcium-activated K+ channel openers in bladder and vascular smooth muscle. Naunyn Schmiedebergs Arch. Pharmacol. (2004) 369(5):481-489.
   PubMedGoogle Scholar
• PERSIANI S, D'AMATO M, MAKOVEC F et al.: Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. Biopharm. Drug Dispos. (2001) 22(2):73-81.
   PubMedGoogle Scholar
• GESSNER G, HELLER R, HOSHI T et al.: The amiodarone derivative 2-methyl-3-(3,5-diiodo-4-carboxymethoxybenzyl)benzofuran (KB130015) opens large-conductance Ca2+-activated K+ channels and relaxes vascular smooth muscle. Eur. J. Pharmacol. (2007) 555(2-3):185-193.
   PubMedGoogle Scholar
• OHWADA T, NONOMURA T, MAKI K et al.: Dehydroabietic acid derivatives as a novel scaffold for large-conductance calcium-activated K+ channel openers. Bioorg. Med. Chem. Lett. (2003) 13(22):3971-3974.
   PubMedGoogle Scholar
• TASHIMA T, TORIUMI Y, MOCHIZUKI Y et al.: Design, synthesis, and BK channel-opening activity of hexahydrodibenzazepinone derivatives. Bioorg. Med. Chem. (2006) 14(23):8014-8031.
   PubMed Web of Science ®Google Scholar
• ZAKHAROV SI, MORROW JP, LIU G et al.: Activation of the BK (SLO1) potassium channel by mallotoxin. J. Biol. Chem. (2005) 280(35):30882-30887.
   PubMedGoogle Scholar

Patents

• BRISTOL-MYERS SQUIBB CO.: WO2004058260 (2004).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US20050080079 (2005).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US7132542 (2006).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US20050080082 (2005).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US20050080105 (2005).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US7002015 (2006).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US7049309 (2006).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US6855829 (2005).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US20050203090 (2005).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US6930100 (2005).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US6916937 (2005).
   Google Scholar
• NEUROSEARCH A/S: WO2006064015 (2006).
   Google Scholar
• NEUROSEARCH A/S: WO2004111017 (2004).
   Google Scholar
• NEUROSEARCH A/S: WO2005023237 (2005).
   Google Scholar
• ANYGEN CO., LTD.: WO2006096030 (2006).
   Google Scholar
• AMERICAN HOME PRODUCTS CORP.: US6288099 (2001).
   Google Scholar
• SMITHKLINE BEECHAM CORP.: WO2005009993 (2005).
   Google Scholar
• TANABE SEIYAKU CO., LTD.: WO2006030977 (2006).
   Google Scholar
• TANABE SEIYAKU CO., LTD.: WO2005115984 (2005).
   Google Scholar
• NIPPON SHINUAKU CO., LTD.: WO9936068 (1999).
   Google Scholar
• NIPPON SHINUAKU CO., LTD.: WO9961016 (1999).
   Google Scholar
• OTSUKA PHARMACEUTICAL CO., LTD.: WO2004075897 (2004).
   Google Scholar
• 4SC AG: US20050070570 (2005).
   Google Scholar
• ROTTAPHARM SPA: CA2514373 (2006).
   Google Scholar
• COLUMBIA UNIVERSITY: WO2006060196 (2006).
   Google Scholar

Websites

• http://www.tanabe.co.jp/english/rd/pipeline.shtml Tanabe R and D policy Accessed 18 January 2007.
   Google Scholar
• http://www.gsk.com/investors/pp_pipeline_standard.htm GlaxoSmithKline investors Accessed 18 January 2007.
   Google Scholar
• http://www.nippon-shinyaku.co.jp/english/news/2007/011607.html Nippon Shinyaku annual reports Accessed 12 March 2007.
   Google Scholar
• http://www.rottapharm.com/pages/canali/r&d/profili/2039.asp Rottapharm group Accessed 13 March 2007.
   Google Scholar